IPW
IMVT icon

Impact Partnership Wealth’s Immunovant IMVT Stock Holding History

Impact Partnership Wealth’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-94
Closed -$1.78K – 1110
2023
Q2 		$1.78K Buy
+94
New +$1.75K ﹤0.01% 701

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Impact Partnership Wealth's IMVT Position: Q3 2023 in Review

Impact Partnership Wealth sold out of Immunovant (IMVT) in Q3 2023, closing a stake of 94 shares — an estimated $1.78K sold.

Impact Partnership Wealth first reported a position in IMVT in Q2 2023 and held it in 1 quarter. The position peaked at $1.78K in Q2 2023. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2023.

  • Impact Partnership Wealth reported no remaining Immunovant position as of Q3 2023 after selling out during the quarter.
  • Impact Partnership Wealth sold 94 Immunovant shares in Q3 2023, an estimated $1.78K.
  • Impact Partnership Wealth first reported a position in Immunovant in Q2 2023 and held it in 1 quarter.
  • Impact Partnership Wealth's Immunovant position peaked at $1.78K in Q2 2023.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.